CoChat
Sign Up
Cited by 561Neurotransmitter Receptor Influence on BehaviorNeural and Behavioral Psychology StudiesNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.

Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis

Open access
Carlezon, William A., Thomas, Mark J.·2009·Neuropharmacology
DOI 10.1016/j.neuropharm.2008.06.075PMC PMC2635333
Open this paper in CoChat — free account

Abstract

The nucleus accumbens (NAc) is a critical element of the mesocorticolimbic system, a brain circuit implicated in reward and motivation. This basal forebrain structure receives dopamine (DA) input from the ventral tegmental area (VTA) and glutamate (GLU) input from regions including the prefrontal cortex (PFC), amygdala (AMG), and hippocampus (HIP). As such, it integrates inputs from limbic and cortical regions, linking motivation with action. The NAc has a well-established role in mediating the rewarding effects of drugs of abuse and natural rewards such as food and sexual behavior. However, accumulating pharmacological, molecular, and electrophysiological evidence has raised the possibility that it also plays an important (and sometimes underappreciated) role in mediating aversive states. Here we review evidence that rewarding and aversive states are encoded in the activity of NAc medium spiny GABAergic neurons, which account for the vast majority of the neurons in this region. While admittedly simple, this working hypothesis is testable using combinations of available and emerging technologies, including electrophysiology, genetic engineering, and functional brain imaging. A deeper understanding of the basic neurobiology of mood states will facilitate the development of well-tolerated medications that treat and prevent addiction and other conditions (e.g., mood disorders) associated with dysregulation of brain motivation systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2008.06.075

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 131 references

Research works printed but not linked: 2

  1. Chen, M.C., Parsegian, A., Carlezon Jr., W.A., 2008. Effect of mesocorticolimbic microinjections of the kappa-opioid agonist U50,488 on intracranial self-stimulation in rats. Soc. Neurosci. Abstr. 34, in press.
  2. DiNieri, 2006, Inducible disruption of CREB activity within nucleus accumbens alters sensitivity to rewarding and prodepressive drugs, Soc. Neurosci. Abstr., 32

Cited by

Sorted by citations

Items 501–561 of 561

Related

See all

Metadata

Authors
Carlezon, W. A., & Thomas, M. J.
Affiliations
  • Harvard University (US)
  • University of Minnesota (US)
Corresponding author
Carlezon, William A.
ORCID
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2009-01
Volume
56
Pages
122-132
ISSN
0028-3908 (ISSN-L)
DOI
10.1016/j.neuropharm.2008.06.075
PMC
PMC2635333
OpenAlex
W1977266070
Cited by
561
References
131
Citations by year
2026: 11 · 2025: 17 · 2024: 21 · 2023: 17 · 2022: 12 · 2021: 22 · 2020: 31 · 2019: 63 · 2018: 25 · 2017: 31 · 2016: 32 · 2015: 33 · 2014: 44 · 2013: 45 · 2012: 47
FWCI
3.05
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (R01DA012736, R01DA019666, DA019666, DA012736)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
nucleus accumbens, reward, aversion, aversive states, mesocorticolimbic system, medium spiny neurons, GABAergic neurons, dopamine, glutamate, ventral tegmental area, prefrontal cortex, amygdala, hippocampus, motivation, addiction, mood disorders, drug reward
MeSH terms
Animals, Avoidance Learning, Nucleus Accumbens, Reward, Illicit Drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review